BB, I agree that AMRN has made some questionable statements that don't jive with public information. Such as generics are incapable of launching GV depending on the outcome of an appeal. I totally recall that at the Nov 2019 AHA conference someone from this board was in attendance and mentioned that Hikma or it's third party supplier presented a slide deck with GV projected sales of $750 million in domestics sales for GV. Raf doesn't recall but somewhere in the archives there's a clip of Hikma available I haven't located yet but will eventually. I respect all your efforts and am all for going after all resources to try and force AMRN to come clean. But at this juncture it's not happening, at the risk of some self disclosure I have extensive background in all facets of the stock market. Amarin will not and should never disclose private talks with potential buyers.
You can turn on a company or someone like a hook on a hot Saturday night can turn a trick. You need to take a nap bro. You are so far off the reservation today even the Indians can't find you.
News 
Market Data 
Discover 
